苯并呋喃-4-羧酸甲酯; 4-苯并呋喃羧酸甲酯 | 41019-56-1

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 苯并呋喃-4-羧酸甲酯; 4-苯并呋喃羧酸甲酯
• 中文别名: 苯并呋喃-4-羧酸甲酯；苯并呋喃-4-羧酸甲酯;4-苯并呋喃羧酸甲酯；苯并呋喃-4-甲酸甲酯；4-苯并呋喃羧酸甲酯
• 英文名称: methyl benzofuran-4-carboxylate
• 英文别名: 4-methoxycarbonylbenzofuran；methyl 1-benzofuran-4-carboxylate
• CAS: 41019-56-1
• 化学式: C₁₀H₈O₃
• 分子量: 176.172
• InChiKey: QUPMFELCGIVSMG-UHFFFAOYSA-N

物化性质

• 沸点：
  258℃
• 密度：
  1.221
• 闪点：
  110℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2932999099
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  存放在室温下，应保持干燥并密封。

反应信息

• 作为反应物：
  描述：

  苯并呋喃-4-羧酸甲酯; 4-苯并呋喃羧酸甲酯 在 正丁基锂 、 草酰氯 、 二异丙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 环己烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 42.5h， 生成
  参考文献：
  名称：

  结核病药物贝达喹啉类似物的构效关系，其中萘单元被双环杂环取代。

  摘要：

  用一系列亲脂性差异很大的双环杂环取代抗结核药物贝达喹啉的萘 C 单元，得到 clogP 值范围为 4.5 倍的类似物。这些化合物的生物学结果表明，该系列中的 clogP 下限平均约为 5.0，可保留针对培养物中M.tb的有效抑制活性（MIC 90 s）。与贝达喹啉相比，一些化合物还显示出对 hERG 通道钾电流的抑制显着降低，但没有共同的结构特征来区分这些化合物。

  DOI：

  10.1016/j.bmc.2018.02.026
• 作为产物：
  描述：

  甲基2-烯丙基-3-羟基苯甲酸酯 在 二甲基硫 、 磷酸 、 臭氧 作用下， 反应 0.92h， 生成 苯并呋喃-4-羧酸甲酯; 4-苯并呋喃羧酸甲酯
  参考文献：
  名称：

  Aminoalkylindoles: Structure-Activity Relationships of Novel Cannabinoid Mimetics

  摘要：

  Aminoalkylindoles (AAIs) are a novel series of cannabinoid receptor ligands. In this report we disclose the structural features of AAIs which are important for binding to this receptor as measured by inhibition of binding of [H-3]Win 55212-2 (5). Functional activity in the mouse vas deferens is also noted and used to distinguish agonists from potential antagonists. The key structural features for potent cannabinoid activity in this series are a bicyclic (naphthyl) substituent at the 3-position, a small (II) substituent at the 2-position, and an aminoethyl (morpholinoethyl) substituent at the 1-position. A 6-bromo analog, Win 54461 (31), has been identified as a potential cannabinoid receptor antagonist. Modeling experiments were done to develop a pharmacophore and also to compare AAI structures with those of classical cannabinoids. The fact that the cannabinoid AAIs arose out of work on a series of cyclooxygenase inhibitors makes sense now that an endogenous cannabinoid ligand has been identified which is a derivative of arachidonic acid. Because of their unique structures and physical properties, AAIs provide useful tools to study the structure and function of the cannabinoid receptor(s).

  DOI：

  10.1021/jm00016a013

文献信息

• Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
  申请人：Molino F. Bruce

  公开号：US20060111385A1

  公开（公告）日：2006-05-25

  The present invention relates to a method of treating disorders including cognition impairment, generalized anxiety disorder, acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder, social anxiety disorder, major depressive disorder, eating disorders, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, substance abuse disorders, chemical dependencies, nicotine addiction, cocaine addiction, alcohol addiction, amphetamine addiction, Lesch-Nyhan syndrome, neurodegenerative diseases, late luteal phase syndrome, narcolepsy, psychiatric symptoms anger, rejection sensitivity, movement disorders, extrapyramidal syndrome, Tic disorder, restless leg syndrome, tardive dyskinesia, sleep related eating disorder, night eating syndrome, stress urinary incontinence, migraine, neuropathic pain, diabetic neuropathy, fibromyalgia syndrome, chronic fatigue syndrome, sexual dysfunction, premature ejaculation, and male impotence. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a disclosed compound. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein.

  本发明涉及一种治疗包括认知障碍、广泛性焦虑障碍、急性应激障碍、社交恐惧症、简单恐惧症、经前期情绪性失调障碍、社交焦虑障碍、重度抑郁障碍、进食障碍、肥胖症、厌食症、暴食症、物质滥用障碍、化学依赖、尼古丁成瘾、可卡因成瘾、酒精成瘾、安非他命成瘾、莱什-尼汉综合征、神经退行性疾病、月经后期综合征、嗜睡症、精神症状愤怒、拒绝敏感性、运动障碍、锥体外症候群、抽动障碍、不安腿综合征、迟发性运动障碍、与睡眠相关的进食障碍、夜间进食综合征、压力性尿失禁、偏头痛、神经痛、糖尿病性神经病变、纤维肌痛综合征、慢性疲劳综合征、性功能障碍、早泄和男性阳痿等多种疾病的方法。该方法涉及向需要此类治疗的患者施用所述化合物的治疗有效量。这些化合物是具有以下IA、IB、IIA、IIB、IIIA或IIIC式的4-苯基取代四氢异喹啉。
• [EN] ANTIBACTERIAL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ANTIBACTÉRIENS ET UTILISATIONS DE CEUX-CI
  申请人：THE GLOBAL ALLIANCE FOR TB DRUG DEV INC

  公开号：WO2017155909A1

  公开（公告）日：2017-09-14

  The present invention relates to compounds of formula (I) including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of tuberculosis.

  本发明涉及式(I)的化合物，包括其任何立体化异构体或其药学上可接受的盐，用于治疗结核病。
• Quinazoline derivatives
  申请人：——

  公开号：US20040044015A1

  公开（公告）日：2004-03-04

  The invention concerns quinazoline derivatives of Formula (I) wherein each of m, R 1 , n, R 2 and R 3 have any of the meanings defined in the description; process for the preparation, pharmaceutical compositions them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

  这项发明涉及式（I）的喹唑啉衍生物，其中m、R1、n、R2和R3中的每一个具有描述中定义的任意含义；制备过程，药物组合物及其在制备用作抗侵袭剂的药物中的使用，用于包含和/或治疗固体肿瘤疾病。
• METHOD FOR THE SYNTHESIS OF 4-BENZOFURAN-CARBOXYLIC ACID
  申请人：Burgos Alain

  公开号：US20090131688A1

  公开（公告）日：2009-05-21

  The invention concerns a novel method for synthesis of 4-benzofuran-carboxylic acid or alkyl ester thereof. This method is characterized in that a reaction for aromatization of a compound of formula (II) is performed for the synthesis of the compound of formula (I), according to the scheme A2 below: wherein R independently represents hydrogen or a linear or branched C 1 - 15 alkyl group. With the invention, it is possible to industrially synthesize 4-benzofuran-carboxylic acid or alkyl ester thereof with good yield and very good purity.

  该发明涉及一种合成4-苯并呋喃羧酸或其烷基酯的新方法。该方法的特点在于，根据下面的方案A2，对式（II）化合物进行芳香化反应以合成式（I）的化合物：其中R独立表示氢或直链或支链的C1-15烷基基团。通过这项发明，可以以良好的产率和非常高的纯度工业化合成4-苯并呋喃羧酸或其烷基酯。
• Benzofuran and dihydrobenzofuran melatonergic agents
  申请人：Bristol-Myers Squibb Company

  公开号：US05856529A1

  公开（公告）日：1999-01-05

  Novel derivatives of benzofuran and dihydrobenzofuran are provided which are useful as melatonergic agents.

  提供了新型苯并呋喃和二氢苯并呋喃衍生物，可用作褪黑素受体激动剂。